268 related articles for article (PubMed ID: 2058872)
1. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.
Rönnblom LE; Alm GV; Oberg KE
Ann Intern Med; 1991 Aug; 115(3):178-83. PubMed ID: 2058872
[TBL] [Abstract][Full Text] [Related]
2. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment.
Rönnblom LE; Alm GV; Oberg K
Acta Oncol; 1991; 30(4):537-40. PubMed ID: 1854511
[TBL] [Abstract][Full Text] [Related]
4. Organ-specific autoimmunity and genetic predisposition in interferon-treated HCV-related chronic hepatitis patients.
Floreani A; Chiaramonte M; Greggio NA; Fabris P; De Lazzari F; Naccarato R; Betterle C
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):71-6. PubMed ID: 9615270
[TBL] [Abstract][Full Text] [Related]
5. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.
Chung YH; Shong YK
Am J Gastroenterol; 1993 Feb; 88(2):244-7. PubMed ID: 8424429
[TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results.
Oberg K; Norheim I; Lind E; Alm G; Lundqvist G; Wide L; Jonsdottir B; Magnusson A; Wilander E
Cancer Treat Rep; 1986 Nov; 70(11):1297-304. PubMed ID: 2429764
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies during alpha-interferon therapy for chronic hepatitis B.
Fattovich G; Betterle C; Brollo L; Pedini B; Giustina G; Realdi G; Alberti A; Ruol A
J Med Virol; 1991 Jun; 34(2):132-5. PubMed ID: 1890413
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis.
Mayet WJ; Hess G; Gerken G; Rossol S; Voth R; Manns M; Meyer zum Büschenfelde KH
Hepatology; 1989 Jul; 10(1):24-8. PubMed ID: 2737600
[TBL] [Abstract][Full Text] [Related]
9. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.
Preziati D; La Rosa L; Covini G; Marcelli R; Rescalli S; Persani L; Del Ninno E; Meroni PL; Colombo M; Beck-Peccoz P
Eur J Endocrinol; 1995 May; 132(5):587-93. PubMed ID: 7749499
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon.
Vallisa D; Cavanna L; Berté R; Merli F; Ghisoni F; Buscarini L
Acta Haematol; 1995; 93(1):31-5. PubMed ID: 7725847
[TBL] [Abstract][Full Text] [Related]
11. Autoimmunity and antibodies to interferons in patients with carcinoid tumors--clinical consequences.
Oberg KE
J Interferon Res; 1994 Aug; 14(4):215-6. PubMed ID: 7822879
[No Abstract] [Full Text] [Related]
12. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis.
Imagawa A; Itoh N; Hanafusa T; Oda Y; Waguri M; Miyagawa J; Kono N; Kuwajima M; Matsuzawa Y
J Clin Endocrinol Metab; 1995 Mar; 80(3):922-6. PubMed ID: 7883851
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment.
Carella C; Mazziotti G; Morisco F; Manganella G; Rotondi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
J Clin Endocrinol Metab; 2001 May; 86(5):1925-9. PubMed ID: 11344186
[TBL] [Abstract][Full Text] [Related]
14. Thyroid autoimmunity and dysfunction associated with type I interferon therapy.
Monzani F; Caraccio N; Dardano A; Ferrannini E
Clin Exp Med; 2004 Apr; 3(4):199-210. PubMed ID: 15103510
[TBL] [Abstract][Full Text] [Related]
15. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study.
Mazziotti G; Sorvillo F; Stornaiuolo G; Rotondi M; Morisco F; Ruberto M; Cioffi M; Amato G; Caporaso N; Gaeta GB; Carella C
J Endocrinol Invest; 2002; 25(7):624-30. PubMed ID: 12150338
[TBL] [Abstract][Full Text] [Related]
16. Thyroid disorders and occurrence of nonorgan-specific autoantibodies (NOSA) in patients with chronic hepatitis C before and during antiviral induction therapy with consensus interferon (interferon alfacon-1).
Hass HG; Klein R; Nehls O; Kaiser S
J Clin Gastroenterol; 2009; 43(5):470-6. PubMed ID: 19247202
[TBL] [Abstract][Full Text] [Related]
17. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.
Conlon KC; Urba WJ; Smith JW; Steis RG; Longo DL; Clark JW
Cancer; 1990 May; 65(10):2237-42. PubMed ID: 2346907
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis.
di Cesare E; Previti M; Russo F; Brancatelli S; Ingemi MC; Scoglio R; Mazzù N; Cucinotta D; Raimondo G
Dig Dis Sci; 1996 Aug; 41(8):1672-7. PubMed ID: 8769300
[TBL] [Abstract][Full Text] [Related]
19. Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature.
Nagayama Y; Ohta K; Tsuruta M; Takeshita A; Kimura H; Hamasaki K; Ashizawa K; Nakata K; Yokoyama N; Nagataki S
Endocr J; 1994 Oct; 41(5):565-72. PubMed ID: 7889118
[TBL] [Abstract][Full Text] [Related]
20. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C.
Watanabe U; Hashimoto E; Hisamitsu T; Obata H; Hayashi N
Am J Gastroenterol; 1994 Mar; 89(3):399-403. PubMed ID: 8122653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
